-transparent.png){kind=logo}
2-chlorodeoxyadenosine (2-CdA) is a new purine analogue which has shown great efficacy in the treatment of hairy cell leukemia. Only one case of cutaneous reaction after this treatment has previously been reported. The data from 33 patients treated with 2-CdA were retrospectively reviewed. Seven of these (21%) developed a disseminated eruption during the month following 2-CdA. One had toxic epidermal necrolysis. A reaction to the associated antibiotic therapy seemed "likely" or "very likely" in 5 out of the 7 cases. The incidence of adverse drug reactions may be increased after 2-CdA, and the role of CD4+ lymphocytopenia in these reactions is discussed.
Related Publications
P Meunier, and
S Castaigne, and
J N Bastie, and
O Chosidow, and
S Aractingi
September 2003,
British journal of haematology,
P Meunier, and
S Castaigne, and
J N Bastie, and
O Chosidow, and
S Aractingi
March 1993,
The New England journal of medicine,
P Meunier, and
S Castaigne, and
J N Bastie, and
O Chosidow, and
S Aractingi
August 2010,
Dermatology reports,
P Meunier, and
S Castaigne, and
J N Bastie, and
O Chosidow, and
S Aractingi
September 1997,
Acta dermato-venereologica,
P Meunier, and
S Castaigne, and
J N Bastie, and
O Chosidow, and
S Aractingi
January 2003,
Journal of B.U.ON. : official journal of the Balkan Union of Oncology,
P Meunier, and
S Castaigne, and
J N Bastie, and
O Chosidow, and
S Aractingi
August 1996,
Journal of the American Academy of Dermatology,
P Meunier, and
S Castaigne, and
J N Bastie, and
O Chosidow, and
S Aractingi
January 1997,
Journal of medicine,
P Meunier, and
S Castaigne, and
J N Bastie, and
O Chosidow, and
S Aractingi
January 1961,
Bulletin de la Societe francaise de dermatologie et de syphiligraphie,
P Meunier, and
S Castaigne, and
J N Bastie, and
O Chosidow, and
S Aractingi
June 1997,
Leukemia & lymphoma,
P Meunier, and
S Castaigne, and
J N Bastie, and
O Chosidow, and
S Aractingi
February 2001,
Clinical and laboratory haematology,
